Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window After successful ...
Trimetazidine on top of standard therapy among patients who’ve undergone PCI for stable angina or NSTE ACS doesn’t affect their long-term outcomes, the ATPCI trial has shown. Participants in the ...
SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a non–ST-elevated myocardial infarction (MI ...
Please provide your email address to receive an email when new articles are posted on . In patients who underwent PCI, trimetazidine, a drug to improve myocardial metabolism, did not improve angina ...
What exactly is optimal medical therapy (OMT) for angina relief? And how long should doctors prescribe it before proceeding to an invasive approach in symptomatic patients with stable ischemic heart ...
Please provide your email address to receive an email when new articles are posted on . There are drug-drug interactions between the COVID-19 treatment ritonavir/nirmatrelvir and various classes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback